Compositions containing ganglioside molecules with enhanced angiogenic activity

Claim 2

A composition with angiogenic activity comprising a mixture of gangliosides in an angiogenically effective amount.

Claim 3

A composition as in claim 1, wherein said composition comprises monosialogangliosides.

Claim 4

A composition as in claim 1, wherein said composition comprises disialogangliosides.

Claim 5

A composition as in claim 1, wherein said composition comprises trisialogangliosides.

Claim 6

A composition as in claim 1, wherein said composition comprises a mixture of mono, di, and trisialogangliosides.

Claim 7

A composition as in claim 1, wherein said composition comprises mono- and di- sialogangliosides.

Claim 8

A composition as in claim 1, wherein said composition comprises mono- and tri-sialogangliosides.

Claim 9

A composition as in claim 1, wherein said composition comprises di- and tri-sialogangliosides.

Claim 10

A composition as in claim 8, wherein said di- and tri-sialogangliosides are in a ratio ranging from about 1 parts disialoganglioside to about 3 parts trisialogangliosides to about 3 parts disialoganglioside to about 1 parts trisialoganglioside.

Claim 11

A composition as in claim 8, wherein said di- and tri-sialogangliosides are present in a ratio of about a part disialoganglioside to about 2 parts trisialoganglioside.

Claim 12

A composition as in claim 1, wherein said composition comprises gangliosides derived from ganglioside containing animal tissue.

Claim 13

A composition as in claim 11, wherein said gangliosides are derived from omental tissue.

Claim 14

A composition as in claim 12, wherein said omental tissue is omental tissue selected from the group consisting of feline, bovine, porcine and canine omental tissue.

Claim 15

A composition as in claim 13, wherein said omental tissue is feline omental tissue.

Claim 16

A comosition as in claim 1, wherein said gangliosides are synthetically produced.

Claim 17

A process for obtaining a composition with enhanced angiogenic activity comprising contacting a sample of angiogenically active ganglioside containing mammalian tissue with a solvent containing chloroform and methanol under conditions favoring extraction of said ganglioside into said solvent, and contacting said ganglioside containing chloroform and methanol mixture with a second solvent containing hexane and ethanol under conditions favoring extraction of said ganglioside into said second solvent, and not angiogenic inhibiting substances, and separating said first and second solvents from each other.

Claim 18

A process for obtaining a composition with enhanced angiogenic activity comprising contacting a sample of angiogenically active ganglioside containing mammalian tissue with a solvent containing chloroform and methanol under conditions favoring extraction of said ganglioside into said solvent, and contacting said ganglioside containing chloroform and methanol mixture with a second solvent containing hexane and ethanol under conditions favoring extraction of said ganglioside into said second solvent, and not angiogenic inhibiting substances, and separating said first and second solvents from each other.

Claim 19

The product of the process of claim 16.

Claim 20

Process as in claim 16, wherein said ganglioside containing second solvent is separated into separate hexane and ethanol phases and said ethanol phase contains said ganglioside.

Claim 21

Process as in claim 18, wherein said ethanol phase is partitioned into an upper and a lower phase by combining with a mixture of chloroform, methanol, and water.

Claim 22

Product of the process of claim 19.

Claim 23

Process as in claim 19, wherein said upper phase is separated into two phases by combining said upper phase, in sequence, with a mixture of methanol and water, and a mixture of chloroform and methanol.

Claim 24

Product of the process of claim 21.

Claim 25

Process as in claim 21, wherein said chloroform-methanol portion is mixed with a mixture of methanol, chloroform, and water, and then a mixture of methanol, chloroform, and sodium aceate, to form two separate portions.

Claim 26

Product of the process of claim 23.

Claim 27

Sodium acetate containing product of the process of claim 23.

Claim 28

A process for obtaining a composition with an angiogenically active ganglioside comprising contacting a ganglioside containing mammalian tissue sample with a mixture of hexane and ethanol under conditions favoring extraction of said angiogenically active ganglioside into said solvent, separating said solvent from said tissue, contacting said angiogenically active ganglioside containing extract with a second solvent of hexane and ethanol under conditions favoring extraction of said angiogenically active ganglioside into said second solvent, removing said hexane, contacting said ganglioside containing ethanol extract with a third solvent containing chloroform, methanol, and water under conditions favoring extraction of said ganglioside into said third solvent, separating said ganglioside containing third solvent into an upper and a lower phase, said upper phase contains said ganglioside, contacting said upper phase with a mixture of methanol and water and a mixture of chloroform and methanol, separating the thus treated upper phase into a methanol and chloroform portin and a methanol and water portion, contacting said methanol and chloroform portin with a mixture of chloroform, methanol and water and a mixture of chloroform, methanol and an acetate containing compound, separating the thus treated methanol and chloroform portion into a first portion containing chloroform, methanol, and water and a second portion containing acetate and purifying said portions, wherein said acetate containing portion contains said ganglioside.

Claim 29

A process for obtaining a composition with an angiogenically active ganglioside comprising contacting a ganglioside containing mammalian tissue sample with a mixture of hexane and ethanol under conditions favoring extraction of said angiogenically active ganglioside into said solvent, separating said solvent from said tissue, contacting said angiogenically active ganglioside containing extract with a second solvent of hexane and ethanol under conditions favoring extraction of said angiogenically active ganglioside into said second solvent, removing said hexane, contacting said ganglioside containing ethanol extract with a third solvent containing chloroform, methanol, and water under conditions favoring extraction of said ganglioside into said third solvent, separating said ganglioside containing third solvent into an upper and a lower phase, said upper phase contains said ganglioside, contacting said upper phase with a mixture of methanol and water and a mixture of chloroform and methanol, separating the thus treated upper phase into a methanol and chloroform portin and a methanol and water portion, contacting said methanol and chloroform portin with a mixture of chloroform, methanol and water and a mixture of chloroform, methanol and an acetate containing compound, separating the thus treated methanol and chloroform portion into a first portion containing chloroform, methanol, and water and a second portion containing acetate and purifying said portions, wherein said acetate containing portion contains said ganglioside.

Claim 30

Method as in claim 26, further comprising contacting said lower portion with separate portions of chloroform, acetone and methanol to form separate fractions thereof.

Claim 31

A method of enhancing angiogenesis in a patient comprising applying to said patient a angiogenically effective amount of the composition of claim 1.

Claim 32

Method of claim 28, wherein said composition is applied orally, intravenously, or topically.